Literature DB >> 1782076

Differential c-myc protein expression in Burkitt's lymphomas and EBV-transformed lymphoblastoid lines.

A D Wennborg1, E Altiok, J P Moore, I Ernberg, G Klein.   

Abstract

The levels of c-myc protein expression in three types of Epstein-Barr virus (EBV) transformed human B-cell derived lines were examined with an ELISA assay. Six independently maintained sublines of the same EBV-transformed pro-B-cell line (FLEB-14), six B-cell lines (LCL) and six Burkitt's lymphoma lines (BL) were compared. The average amount of c-myc protein, calculated from at least three independent tests on each line, differed between the three groups. Expressed in relative units, the ratio of the means was 1:2:5 for the LCL:FLEB:BL lines. The differences were statistically significant at P less than 0.01.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1782076     DOI: 10.1016/0277-5379(91)90436-h

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  3 in total

1.  Prognostic significance of cell proliferation and apoptosis-regulating proteins in Epstein-Barr Virus positive and negative pediatric non-Hodgkin's lymphoma.

Authors:  Safiye Aktaş; Aydanur Kargi; Nur Olgun; Gulden Diniz; Ayşe Erbay; Canan Vergin
Journal:  Pathol Oncol Res       Date:  2009-09       Impact factor: 3.201

2.  Nanofluidic proteomic assay for serial analysis of oncoprotein activation in clinical specimens.

Authors:  Alice C Fan; Debabrita Deb-Basu; Mathias W Orban; Jason R Gotlib; Yasodha Natkunam; Roger O'Neill; Rose-Ann Padua; Liwen Xu; Daryl Taketa; Amy E Shirer; Shelly Beer; Ada X Yee; David W Voehringer; Dean W Felsher
Journal:  Nat Med       Date:  2009-04-12       Impact factor: 53.440

3.  Reliable cell and tissue morphology-based diagnosis of endemic Burkitt lymphoma in resource-constrained settings in Ghana.

Authors:  Cecilia Smith-Togobo; Mette Ø Pedersen; Steffen G Jensen; Babatunde Duduyemi; Richard K Gyasi; Michael F Ofori; Vivian Paintsil; Lorna Renner; Peter Nørgaard; Lars Hviid
Journal:  BMC Cancer       Date:  2019-12-30       Impact factor: 4.430

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.